ストックスクリーナーアプリを入手
3.86
2.81%
-0.1117
アフターアワーズ：
3.86
前日終値:
$3.9717
開ける：
$4.0797
24時間の取引高:
9,169
Relative Volume:
0.42
時価総額：
$21.57M
収益：
-
当期純損益:
$-14.29M
株価収益率:
-0.698
EPS:
-5.53
ネットキャッシュフロー:
$-12.27M
1週間 パフォーマンス:
-9.18%
1か月 パフォーマンス:
+48.46%
6か月 パフォーマンス:
-27.85%
1年 パフォーマンス:
-3.50%
1日の値動き範囲:
$3.85
$4.0797
1週間の範囲:
$3.82
$4.42
52週間の値動き範囲:
$2.1501
$8.8465
Aprea Therapeutics Inc Stock (APRE) Company Profile
名前
Aprea Therapeutics Inc
セクター
電話
617-463-9385
住所
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-06-22 | 開始されました | H.C. Wainwright | Neutral |
| 2020-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2019-10-28 | 開始されました | JP Morgan | Neutral |
| 2019-10-28 | 開始されました | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aprea Therapeutics Inc (APRE) 最新ニュース
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN
DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR
Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews
Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa
Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World
Aprea therapeutics director sells shares worth $29,583 - Investing.com India
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com
Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK
Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha
Aprea reports safe trial results for new cancer drug - Investing.com
Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News
Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St
Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India
Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com
Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa
Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia
Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo
Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India
Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada
Director Bernd Seizinger Acquires 10,000 Shares of Aprea Therape - GuruFocus.com
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit - ForexTV.com
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo
Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc - Yahoo Finance
Stonepine Capital Management, LLC Increases Stake in Aprea Thera - GuruFocus.com
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - ForexTV.com
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and - EIN News
Aprea Therapeutics Welcomes Dr. Philippe Pultar as Senior Medical Advisor - MyChesCo
Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo
APRE stock touches 52-week low at $2.22 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.22 amid market challenges - Investing.com UK
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development - The Manila Times
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MSN
Halda appoints new chief executive - The Pharma Letter
Stonepine Capital Management LLC Acquires Shares of 137,174 Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Halda Therapeutics Appoints Christian Schade as CEO - citybiz
Aprea Therapeutics Inc (APRE) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):